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Screening of blood-derived microRNAs for 
tomorrow’s diagnosis
The first connection between microRNAs (miRNAs) and 
the pathogenesis of cancer was described by Calin et al. 
in 2002 [1]. Since then, it has become clear that miRNA 
expression patterns reflect the identities of both normal 
and  malignant  cells.  The  majority  of  reported  miRNA 
expression data have been generated from solid tissues, 
but differentially expressed microRNAs have also been 
identified in body fluids, such as serum and cerebrospinal 
fluid [2]. This finding has led researchers to explore the 
diagnostic and predictive relevance of miRNAs in whole 
blood, the most accessible organ of the human body.
In  an  article  recently  published  in  Nature  Methods, 
Keller and colleagues [3] addressed this issue by investi­
gating  the  miRNA  transcriptome  (which  they  call  the 
‘miRNome’) of blood samples from patients with a variety 
of diseases, including lung cancer and myocardial infarc­
tion. A total of 454 blood samples, taken from individuals 
affected by one of 14 selected diseases (Box 1) or from 
healthy controls, were profiled using miRNA microarray 
technology.  This  led  to  the  identification  of  multiple 
miRNAs that are deregulated in the disease state, that is, 
their  expression  was  either  up­  or  down­regulated  in 
patient  samples  compared  with  matched  controls.  The 
dysregulated miRNA profiles could be used to discri  mi­
nate between healthy controls and patient samples with 
an average accuracy of 88.5%, or 72.5% using only two 
miRNAs. Considering the lack of diagnostic markers for 
many diseases, the work of Keller et al. [3] highlights the 
potential  for  the  future  integration  of  blood­based 
miRNAs into routine diagnostics.
Serum, plasma or whole blood?
Despite the high discriminative potential, the predictive 
value of the total miRNome amounted on average to only 
67.45%.  Confounding  variables  for  this  experimental 
approach  include  existing  co­morbidities  and  varying 
number of cells in the blood (blood counts), which might 
distort  disease­specific  miRNA  profiles.  The  hetero­
geneity  of  blood,  which  is  a  mixture  of  platelets, 
erythrocytes, myeloid cells and lymphoid cells, might be 
another source of confounding factors.
Until  now,  most  published  studies  focused  on  the 
detection of miRNAs from serum. However, the study by 
Keller and colleagues [3] demonstrate that miRNomes of 
blood cells can reflect the presence of diseases that are 
not  necessarily  blood­borne.  It  is  not  fully  understood 
how  the  various  types  of  blood  cell  change  their 
miRNome in response to disease; neither is it understood 
which cells in the hematopoietic system alter to reflect 
individual  disease.  Could  it  be  that  the  miRNome  of 
monocytes is altered following myocardial infarction, a 
necrotic  condition,  whereas  immune  diseases  induce 
changes in the miRNome of B lymphocytes? To answer 
this question, a direct comparison between the miRNomes 
of serum, whole blood samples and hematopoietic sub­
populations, such as lymphocytes, from different diseases 
would be helpful. The use of serum might decrease the 
above mentioned confounding variables, possibly allow­
ing the detection of a more concentrated disease­related 
miRNome by decreasing blood cell­related background 
expression  of  miRNAs  through  co­morbidities,  for 
example. In addition, most published works focused on 
the  comparison  between  serum­derived  miRNomes  of 
healthy controls with one particular disease. However, a 
comparison  between  whole  blood  and  serum  across 
multiple  malignant  and  non­malignant  diseases  is  still 
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approach has more of a predictive miRNome.
miRNAs: new tools for the pathologist?
Many studies have demonstrated that miRNA expression 
patterns  can  classify  cancers  and  form  cancer­specific 
networks  describing  the  developmental  lineage  and 
differentiation  state  of  tumors  [4,5].  However,  is  this 
enough to justify the integration of miRNAs into routine 
diagnostics? The answer depends on the type of cancer. A 
major  problem  lies  in  the  varying  number  of  miRNAs 
necessary  to  distinguish  and  classify  specific  cancer 
entities. For example, the number of miRNAs that are 
predictors for different classes of acute myeloid leukemias 
(AML) with genetic abnormalities varies between 7 and 
48  using  a  real­time  PCR  approach  [6],  whereas  a 
signature involving only 4 miRNAs (miR­128a, miR­128b, 
miR­223  and  let­7b)  accurately  discriminates  between 
AMLs and acute lymphoblastic leukemias (ALLs) [7]. In 
addition, expression levels of a single miRNA, miR­181a, 
constitute  a  prognostic  factor  for  overall  survival  in 
normal karyotype leukemia. If cancer is considered to be 
a developmental process similar to hematopoiesis [8,9], 
these findings might imply that miRNA expression alters 
hierarchically  to  reflect  different  stages  within  cancer 
development.  Multiple  miRNA  predictors  have  been 
developed to classify differentiation stages of cancers; a 
useful tool, especially for cancers of unknown primary 
origin [10]. Yet it is still not clear whether these findings 
using  tissue  samples  are  mirrored  by  serum­based 
miRNA markers.
Challenges for miRNA-based diagnostics
The study of Keller et al. [3] strengthens the concept of 
blood­borne  miRNAs  as  biomarkers  for  disease. 
Tech  nical limitations include a lack of existing standards 
that would allow cross­comparisons between laboratories 
and patient samples from various locations. In addition, 
diagnostic tests for miRNAs need to be simplified and 
streamlined for rapid readout. This would allow a better 
integration into established pathological scoring systems 
that would eventually benefit patients. To this end, more 
diseases  have  to  be  screened  for  blood­borne  miRNA 
expression profiles and correlated with clinical features. 
For now, miRNAs are only a fragment of the truth.
Abbreviations
AML, acute myeloid leukemia; miRNA, microRNA; miRNome, miRNA 
transcriptome.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We would like to thank Arefeh Rouhi for helpful discussion and reading of the 
manuscript.
Author details
1Department of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, 
Germany. 2Institute of Experimental Cancer Research, Comprehensive Cancer 
Center, University Hospital of Ulm, 89081 Ulm, Germany.
Published: 23 November 2011
References
1.  Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, 
Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent 
deletions and down-regulation of micro-RNA genes miR15 and miR16 at 
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 
99:15524-15529.
2.  Scholer N, Langer C, Dohner H, Buske C, Kuchenbauer F: Serum microRNAs 
as a novel class of biomarkers: a comprehensive review of the literature. 
Exp Hematol 2010, 38:1126-1130.
3.  Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, 
Giese N, Tjaden C, Ott K, Werner J, Hackert T, Ruprecht K, Huwer H, Huebers J, 
Jacobs G, Rosenstiel P, Dommisch H, Schaefer A, Muller-Quernheim J, Wullich 
B, Keck B, Graf N, Reichrath J, Vogel B, Nebel A, Jager SU, Staehler P, Amarantos 
I, Boisguerin V, et al.: Toward the blood-borne miRNome of human diseases. 
Nat Methods 2011, 8:841-843.
4.  Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, 
Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: 
MicroRNA expression profiles classify human cancers. Nature 2005, 
435:834-838.
5.  Starczynowski DT, Morin R, McPherson A, Lam J, Chari R, Wegrzyn J, 
Kuchenbauer F, Hirst M, Tohyama K, Humphries RK, Lam WL, Marra M, Karsan 
A: Genome-wide identification of human microRNAs located in leukemia-
associated genomic alterations. Blood 2011, 117:595-607.
6.  Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B: MicroRNA 
expression profiling in relation to the genetic heterogeneity of acute 
myeloid leukemia. Blood 2008, 111:5078-5085.
7.  Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, 
Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J: 
MicroRNA expression signatures accurately discriminate acute 
lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci 
U S A 2007, 104:19971-19976.
8.  Petriv OI, Kuchenbauer F, Delaney AD, Lecault V, White A, Kent D, Marmolejo 
L, Heuser M, Berg T, Copley M, Ruschmann J, Sekulovic S, Benz C, Kuroda E, 
Ho V, Antignano F, Halim T, Giambra V, Krystal G, Takei CJ, Weng AP, Piret J, 
Eaves C, Marra MA, Humphries RK, Hansen CL: Comprehensive microRNA 
expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A 
2010, 107:15443-15448.
9.  Petriv OI, Hansen CL, Humphries RK, Kuchenbauer F: Probing the complexity 
of miRNA expression across hematopoiesis. Cell Cycle 2011, 10:2-3.
Box 1. The 14 diseases profiled by Keller et al. [3]
Prostate cancer
Acute myocardial infarction
Chronic obstructive pulmonary disease
Gastric tumors
Lung cancer
Melanoma
Multiple sclerosis
Ovarian cancer
Pancreatic ductal adenocarcinoma
Pancreatic tumors
Pancreatitis
Periodontitis
Sarcoidosis
Wilms’ tumor
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